Compare Stocks

→ Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MXCT MaxCyte	$3.74 -1.6%	$4.27	$2.45 ▼ $5.55	$390.46M	1.34	630,420 shs	145,445 shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MXCT MaxCyte	-4.04%	-4.76%	-14.03%	-24.90%	-23.85%

The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MXCT MaxCyte	1.819 of 5 stars	3.5	2.0	0.0	0.0	1.1	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MXCT MaxCyte	3.00	Buy	$8.67	131.73% Upside

Current Analyst Ratings

Latest CSRT, EKF, OXB, and MXCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/23/2024	MXCT MaxCyte	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00
3/13/2024	MXCT MaxCyte	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
3/13/2024	MXCT MaxCyte	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00
3/13/2024	MXCT MaxCyte	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/5/2024	MXCT MaxCyte	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MXCT MaxCyte	$41.29M	9.46	N/A	N/A	$2.23 per share	1.68

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MXCT MaxCyte	-$37.92M	-$0.37	N/A	N/A	N/A	-91.85%	-15.90%	-13.94%	5/7/2024 (Confirmed)

Latest CSRT, EKF, OXB, and MXCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2024	N/A	MXCT MaxCyte	-$0.14	N/A	+$0.14	N/A	N/A	N/A
3/12/2024	Q4 2023	MXCT MaxCyte	-$0.10	-$0.05	+$0.05	-$0.05	$15.60 million	$15.67 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MXCT MaxCyte	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MXCT MaxCyte	N/A	10.65	9.97

Ownership

Institutional Ownership

Company	Institutional Ownership
MXCT MaxCyte	68.81%

Insider Ownership

Company	Insider Ownership
MXCT MaxCyte	6.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
MXCT MaxCyte	143	104.40 million	98.13 million	Optionable

CSRT, EKF, OXB, and MXCT Headlines

Source	Headline
	MaxCyte (NASDAQ:MXCT) Receives "Overweight" Rating from Stephens americanbankingnews.com - April 24 at 5:26 AM
	MaxCyte (NASDAQ:MXCT) Receives Overweight Rating from Stephens marketbeat.com - April 23 at 11:56 AM
	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 globenewswire.com - April 10 at 8:05 AM
	Mesa Laboratories maintains quarterly dividend of $0.16 msn.com - April 5 at 1:52 AM
	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) globenewswire.com - April 2 at 8:05 AM
	Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 5,000 Shares of Stock insidertrades.com - March 29 at 8:56 AM
	John Joseph Johnston Sells 5,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock marketbeat.com - March 28 at 7:55 PM
	Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term finance.yahoo.com - March 17 at 8:04 AM
	MaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance finanznachrichten.de - March 15 at 8:07 AM
	MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates finance.yahoo.com - March 14 at 10:45 AM
	MaxCyte Shares Rise 13% After 4Q Beat, Reaffirmed Guidance marketwatch.com - March 13 at 8:22 AM
	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance globenewswire.com - March 12 at 4:05 PM
	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance globenewswire.com - March 12 at 4:05 PM
	MaxCyte, Inc.: MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results finanznachrichten.de - March 6 at 4:53 PM
	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results globenewswire.com - March 4 at 4:05 PM
	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results globenewswire.com - March 4 at 4:05 PM
	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences finance.yahoo.com - February 9 at 8:25 AM
	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers finance.yahoo.com - January 30 at 9:41 AM
	MaxCyte Signs SPL Agreement With Imugene markets.businessinsider.com - January 23 at 1:02 PM
	Why Cell Engineering Company MaxCyte Shares Are Up Today msn.com - January 9 at 1:07 PM
	COMM, NKTX and AVIR are among after hour movers seekingalpha.com - January 9 at 8:07 AM
	MaxCyte Stock (NASDAQ:MXCT) Dividends: History, Yield and Dates benzinga.com - January 5 at 9:06 AM
	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell ... bakersfield.com - January 3 at 9:13 AM
	MaxCyte teams with Singapore-based Lion to support TCR-T cell work shareprices.com - January 3 at 9:13 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

MaxCyte

NASDAQ:MXCT

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial